title: Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
abstract: A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC) to receive one of two cisplatin (Platinol)-based chemotherapy regimens: Paclitaxel (Taxol) 175 mg/m2 given by 3-hour infusion followed by cisplatin 80 mg/m2 on day 1; Or cisplatin 80 mg/m2 on day 1, followed by teniposide (Vumon) 100 mg/m2 given on days 1, 3, and 5. Cycles were repeated every 3 weeks. Preliminary analysis of the results of this phase III trial shows that hematologic toxicity was decidedly more severe in the group treated with cisplatin/teniposide than in those given paclitaxel/cisplatin. Of 264 patients evaluable so far, responses have been observed in 47% of those given paclitaxel and in 29% of those treated with teniposide. However, extramural radiologic response evaluation is still under way, so these figures are expected to change somewhat. It appears clear that the paclitaxel-based therapy affords a benefit in terms of response and toxicity, but survival results are premature and any definite conclusions await final analysis.
authors.affiliation: University Hospital, Vrije Universiteit Amsterdam, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
authors.forename: P E
authors.initials: PE
authors.lastname: Postmus
authors.forename: T A
authors.initials: TA
authors.lastname: Splinter
authors.forename: M
authors.initials: M
authors.lastname: Diaz-Puente
authors.forename: N
authors.initials: N
authors.lastname: Van Zandwijk
authors.forename: G
authors.initials: G
authors.lastname: Scagliotti
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: J
authors.initials: J
authors.lastname: Van Meerbeeck
authors.forename: C
authors.initials: C
authors.lastname: Debruyne
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D013534:Survival; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D013713:Teniposide; D017239:Paclitaxel; D002945:Cisplatin